Product Reports Resources Pricing Login Book a demo

Inflammatix

Biotech & Life Sciences · Sunnyvale, United States · Founded 2016

Developing novel molecular diagnostics for acute infections and sepsis that work by 'reading' the immune system MoreLess

Inflammatix is a pioneering startup in the healthcare diagnostics sector, focusing on developing rapid point-of-care tests that read the immune system. The company aims to revolutionize how infections are diagnosed by leveraging a novel approach that examines the body's immune response rather than just looking for pathogens directly. This method allows for the accurate identification of bacterial and viral infections, as well as the severity of these infections, which is crucial for conditions like sepsis.

The primary clients for Inflammatix are healthcare providers, including hospitals, clinics, and urgent care centers. These institutions benefit from the company's technology by being able to make quicker and more accurate decisions regarding antibiotic prescriptions and patient admissions. This is particularly important in the context of acute infections, where timely and precise diagnosis can significantly impact patient outcomes.

Inflammatix operates in the medical diagnostics market, a rapidly growing sector driven by the increasing need for quick and reliable diagnostic solutions. The company's business model is centered around the development and commercialization of its diagnostic tests. Although their tests are not yet FDA-approved or CE-marked, they have been validated in numerous independent studies involving thousands of patients and published in leading medical journals.

Revenue generation for Inflammatix primarily comes from the sale of its diagnostic tests and related services. As the company continues to advance its technology and secure regulatory approvals, it is poised to capture a significant share of the diagnostics market, particularly in the areas of infectious diseases and sepsis.

In summary, Inflammatix is at the forefront of medical diagnostics innovation, offering rapid and accurate immune system-based tests to healthcare providers. The company is well-positioned to address major clinical and public health challenges, making it a valuable player in the healthcare industry.

Keywords: diagnostics, immune system, infections, sepsis, healthcare, rapid tests, bacterial, viral, point-of-care, innovation.

Company overview

Inflammatix company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2016
Headquarters
Sunnyvale, United States
Employees
76
Open positions
None listed
Dealroom signal
66.6
client focusb2btechnologyBig Datasub industryPharmaceuticalsub industryBioTechnologysectorPersonal Healthbusiness modelManufacturingsectorTestingindustryHealthsectorBiotechnologysectorGenetics and genomicssectorPrecision MedicinesectorImmune SystemsectorHealth DiagnosticssectorSpinout

Valuation & funding

Inflammatix funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES EOther financing Sep 2024 $57M $228M Vesalius Biocapital Partners · Northpond Ventures · Khosla Ventures · OSF
LATE VCOther financing Jan 2023 $0 Iberis Capital
LATE VCOther financing Nov 2021 $12M $48M US Department of Health and Human Services
GRANTOther financing Nov 2021 $1.7M National Institutes of Health
SERIES DOther financing Mar 2021 $102M $408M Think.Health · Northpond Ventures · D1 Capital Partners · Khosla Ventures
GRANTOther financing Sep 2020 DARPA
SERIES COther financing Jan 2020 Grey Sky Venture Partners · Northpond Ventures · Khosla Ventures · Think.Health
SERIES BOther financing Oct 2018 Northpond Ventures · Think.Health
SERIES AOther financing Mar 2017 Khosla Ventures
GRANTOther financing Jan 2017 DARPA
Showing 10 recorded eventsUnlock the complete deal history →

Growth signals

Inflammatix website traffic

Latest recorded traffic for Inflammatix is 2.4K monthly website visits, down 42.9% over the last three months. Inflammatix's team grew 0% over the past year.

Latest monthly visits2.4K 3-month web change-42.9% 1-year team growth0%
Monthly website visits103 observations · Oct 2017–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Inflammatix compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Inflammatix's talent

Book a demo to see the people
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 6 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

13 investors on Inflammatix's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 2 investors entered at this stage
DARPA
National Institutes of Health
Series A 3 investors entered at this stage
Khosla Ventures
Northpond Ventures
Think.Health
Series B+ 7 investors entered at this stage
Grey Sky Venture Partners
D1 Capital Partners
OSF
US Department of Health and Human Services
Iberis Capital
Vesalius Biocapital Partners
Raw Ventures
Other known 1 additional known investor
Stanford University

Global footprint

Where Inflammatix has talent and traffic

Workforce by country
3 countries with
team presence
🇺🇸 United States78.2%
🇵🇹 Portugal20%
🇬🇷 Greece1.8%
3 countries shown

In the news

Latest news about Inflammatix

Recent press, funding announcements, and product moves mentioning Inflammatix — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Inflammatix

An AI-synthesized read of the highest-engagement posts about Inflammatix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inflammatix’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.